Estados Unidos · Plataformas y datos · Yahoo Finance

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Publicado por Yahoo Finance · Estados Unidos hace 10 h

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar

The Motley Fool

Axon Enterprise vs. ServiceNow: Which Industrials Stock Is a Better Buy in 2026?

Tenet Healthcare Q3 Earnings Call Highlights

First Business outlines ~10% annual loan growth and sees NIM staying above 3.60%–3.65% long-term range

Hedge fund Arini sells $800 million in debt as losses mount - WSJ

Has the tech bubble burst? Why the Nasdaq’s rough ride looks eerily like 2000.

CNBC is at the Fort Lauderdale International Boat Show